NUP98 and acute myeloid leukemia: In a cohort of 237 patients treated within the AML-BFM 2004 and 2012 protocols and with sufficient material for re-analysis, we observed favorable outcomes for 3-year EFS of 61% and 69% and OS of 79% and 90% in patients without WT1 mutations or NUP98-NSD1 fusion or with only one of these factors.